Pediatric Haemophilus Influenzae Infection Medication
- Author: Mobeen H Rathore, MD, CPE, FAAP, FIDSA; Chief Editor: Russell W Steele, MD more...
Antibiotic agents
Class Summary
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. Aggressive parenteral antibiotic therapy is required for severe forms of Haemophilus influenzae disease, particularly those caused by the type b strain. More mild forms of disease (ie, sinopulmonary infections caused by nontypeable strains of Haemophilus organisms) may be treated with various oral antibiotics. Only therapies for invasive H influenzae infection are reviewed here.
Third-generation cephalosporins have become the cornerstone of therapy for invasive H influenzae infections, including meningitis, because of their potent bacteriocidal activity and penetration into the subarachnoid space.
Semisynthetic penicillins, particularly ampicillin, may be useful in H influenzae meningitis if the isolate is beta-lactamase negative.
Ceftriaxone (Rocephin)
Third-generation cephalosporin with broad-spectrum gram-negative activity, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. Arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Cefotaxime (Claforan)
Arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms.
Cefepime (Maxipime)
So-called fourth-generation cephalosporin with good gram-negative coverage. Similar to third-generation cephalosporins but has better gram-positive coverage. Excellent penetration into CNS; indicated for treatment of adult and pediatric meningitis.
Meropenem (Merrem)
Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell-wall synthesis. Effective against most gram-positive and gram-negative bacteria. Has slightly increased activity against gram-negative species and slightly decreased activity against staphylococci and streptococci compared with imipenem. In contrast to imipenem, indicated for treatment of bacterial meningitis, including pediatric meningitis.
Chloramphenicol (Chloromycetin)
Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria.
Ampicillin (Marcillin, Omnipen, Polycillin, Principen)
Agent with cell wall activity that interferes with transpeptidation step of peptidoglycan biosynthesis. Has bactericidal activity against susceptible organisms. Resistance of H influenzae to ampicillin occurs in 10-40% of patients. Use in combination with chloramphenicol.
Glucocorticoids
Class Summary
Glucocorticosteroids elicit anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli. Use of adjunctive glucocorticosteroid therapy has been demonstrated to decrease the risk of sensorineural deafness in children with H influenzae meningitis.
Dexamethasone (Decadron)
For various allergic and inflammatory diseases. Decreases inflammation by suppressing migration of PMNs and reducing capillary permeability. For maximum benefit, corticosteroids should be initiated as soon as possible in treatment of H influenzae meningitis, ideally prior to the first dose of antibiotics.
Vaccines
Class Summary
Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components, which act as antigens. Administration of the vaccine stimulates production of antibodies with specific protective properties. For a complete overview of current vaccine recommendations, see the Advisory Committee on Immunization Practices (ACIP) guidelines from the Centers for Disease Control and Prevention (CDC).[6]
Haemophilus influenza type b vaccine (ActHIB)
Used for routine immunization of children against invasive diseases caused by H influenzae type b by decreasing nasopharyngeal colonization. CDC's ACIP recommends that all children receive one of the conjugate vaccines licensed for infant use beginning routinely at age 2 mo.
Chemoprophylaxis
Class Summary
Chemoprophylaxis is used to prevent secondary disease. With widespread success of immunization, chemoprophylaxis now is of mostly historical interest.
Rifampin (Rimactane, Rifadin)
Inhibits RNA synthesis in bacteria by binding to beta subunit of DNA-dependent RNA polymerase, which in turn blocks RNA transcription.
[Best Evidence] Santibanez TA, Shefer A, Briere EC, Cohn AC, Groom AV. Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States. Vaccine. Jan 20 2012;30(5):941-7. [Medline].
[Best Evidence] CDC. Invasive Haemophilus influenzae type b disease in five young children--Minnesota, 2008. MMWR. January 2009;58:58-60. [Medline]. [Full Text].
Burns IT, Zimmerman RK. Haemophilus influenzae type B disease, vaccines, and care of exposed individuals. J Fam Pract. Sep 2000;49(9 Suppl):S7-13; quiz S14. [Medline].
Friesen CA, Cho CT. Characteristic features of neonatal sepsis due to Haemophilus influenzae. Rev Infect Dis. 1977;8:777. [Medline].
Lessner A, Stern GA. Preseptal and orbital cellulitis. Infect Dis Clin North Am. Dec 1992;6(4):933-52. [Medline].
Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Dec 1 2006;55:1-48. [Medline]. [Full Text].
Ward J, Lieberman JM, Cochi S. Haemophilus influenzae vaccines. In: Plotkin S, Mortimer E, eds. Vaccines. 1994:337.
[Best Evidence] [Guideline] CDC. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommnedations for use of Hib vaccine. MMWR. 2009;58:1008-1009. [Medline]. [Full Text].
Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J Pediatr. Mar 1979;94(3):355-64. [Medline].
Hamlin J, Senthilnathan S, Bernstein HH. Update on universal childhood immunizations. Curr Opin Pediatr. Aug 2008;20(4):483-9. [Medline].
Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med. Oct 13 1988;319(15):964-71. [Medline].
Murphy TF, Apicella MA. Nontypable Haemophilus influenzae: a review of clinical aspects, surface antigens, and the human immune response to infection. Rev Infect Dis. Jan-Feb 1987;9(1):1-15. [Medline].
Rubin LG, Moxon ER. Pathogenesis of bloodstream invasion with Haemophilus influenzae type b. Infect Immun. Jul 1983;41(1):280-4. [Medline].
Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev. 1991;13:113-42. [Medline].
St Geme JW. The pathogenesis of nontypable Haemophilus influenzae otitis media. Vaccine. 2000;8; Suppl 1:S41-50. [Medline].

